Key points are not available for this paper at this time.
Design
Review
Myocardial stunning may be driven by molecular defects at the contractile apparatus level, specifically selective proteolysis of troponin I.
Myocardial stunning is a form of ischemic injury, which occurs with transient ischemia followed by re-establishment of flow, and which results in reversible cardiac dysfunction. There is evidence that the molecular defect in stunning is at the level of the contractile apparatus. Selective proteolysis of the myofilament protein, troponin I, appears to underlie the phenotype of stunning in some models, but other myofilament protein modifications may also have a role.
No takes yet. Share an insight, caveat, or question.
Eyk et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: